Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Iterum Therapeutics (Nasdaq: ITRM), a developer of next-generation oral and IV antibiotics for multi-drug resistant pathogens, announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 14, 2024. The company will host a conference call at 8:30 a.m. ET on the same day to discuss financial results and provide a business update. Investors can access the call via phone or audio webcast through the company's website.
Iterum Therapeutics (Nasdaq: ITRM), sviluppatore di antibiotici orali e IV di nuova generazione per patogeni multi-resistenti, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura dei mercati statunitensi giovedì 14 novembre 2024. L'azienda ospiterà una conferenza telefonica alle 8:30 ET dello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento sull'attività. Gli investitori possono accedere alla chiamata via telefono o tramite webcast audio attraverso il sito web dell'azienda.
Iterum Therapeutics (Nasdaq: ITRM), un desarrollador de antibióticos orales e IV de próxima generación para patógenos multirresistentes, anunció que publicará sus resultados financieros del tercer trimestre 2024 antes de la apertura del mercado estadounidense el jueves 14 de noviembre de 2024. La compañía realizará una llamada de conferencia a las 8:30 a.m. ET ese mismo día para discutir los resultados financieros y proporcionar una actualización del negocio. Los inversores pueden acceder a la llamada por teléfono o a través de la transmisión de audio en el sitio web de la empresa.
Iterum Therapeutics (Nasdaq: ITRM)는 다제내성 병원체를 위한 차세대 경구 및 IV 항생제를 개발하는 회사로, 2024년 11월 14일 목요일 미국 시장 개장 전에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 30분 ET에 재무 결과를 논의하고 사업 업데이트를 제공하기 위해 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 회사 웹사이트를 통해 전화 또는 오디오 웹캐스트로 통화에 접속할 수 있습니다.
Iterum Therapeutics (Nasdaq: ITRM), un développeur d'antibiotiques oraux et IV de nouvelle génération pour les pathogènes multirésistants, a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés américains le jeudi 14 novembre 2024. La société organisera une conférence téléphonique à 8h30 ET le même jour pour discuter des résultats financiers et fournir une mise à jour sur l'activité. Les investisseurs peuvent accéder à l'appel par téléphone ou via l'audioconférence sur le site web de l'entreprise.
Iterum Therapeutics (Nasdaq: ITRM), ein Entwickler von neuartigen oralen und intravenösen Antibiotika gegen multiresistente Erreger, kündigte an, dass es seine Finanzergebnisse für das dritte Quartal 2024 vor der Eröffnung der US-Märkte am Donnerstag, den 14. November 2024, veröffentlichen wird. Das Unternehmen wird an diesem Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, um die Finanzergebnisse zu besprechen und ein Update zum Geschäft zu geben. Investoren können an der Konferenz über das Telefon oder die Audio-Webcast-Funktion über die Unternehmenswebsite teilnehmen.
- None.
- None.
DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Thursday, November 14, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 969798. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/167259520. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will Iterum Therapeutics (ITRM) report Q3 2024 earnings?
How can investors join Iterum Therapeutics (ITRM) Q3 2024 earnings call?
Where can I find Iterum Therapeutics (ITRM) Q3 2024 earnings webcast?
